Reacting to consumer outrage over insulin prices, drugmaker Eli Lilly and Company says it will reduce the sticker prices of several products that are used by diabetes patients and whose prices Lilly
has repeatedly increased in the past. "Lilly also said it would cap at $35 a month what patients pay out of their own pockets for the company’s insulin — even though the company already
had such a policy in place," per
The New York Times. "Lilly has been a primary contributor to soaring prices for an injection that millions of Americans rely on to keep their blood sugar at
levels that will keep them alive. The announcement comes at a time of mounting political pressure on drug companies to rein in what lawmakers and other critics view as the industry’s pattern of
abusive profiteering."
advertisement
advertisement
Read the whole story at The New York Times »
